|
gptkbp:instance_of
|
gptkb:United_States_federal_law
|
|
gptkbp:administered_by
|
gptkb:Food_and_Drug_Administration_(FDA)
|
|
gptkbp:affects
|
drug availability
|
|
gptkbp:amended_by
|
Subsequent legislation
|
|
gptkbp:amends
|
gptkb:Federal_Food,_Drug,_and_Cosmetic_Act
|
|
gptkbp:date_enacted
|
gptkb:1984
|
|
gptkbp:enacted_by
|
gptkb:United_States_Congress
|
|
gptkbp:encourages
|
competition in the pharmaceutical market
|
|
gptkbp:facilitates
|
the approval of generic drugs
|
|
gptkbp:governing_body
|
high drug prices
|
|
gptkbp:has_implications_for
|
gptkb:pharmaceuticals
public health
|
|
gptkbp:has_influenced
|
international drug approval processes
|
|
gptkbp:has_led_to
|
increased access to medications
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Hatch-Waxman Act
|
|
gptkbp:influences
|
drug pricing in the United States
|
|
gptkbp:involves
|
patent litigation between brand-name and generic manufacturers
|
|
gptkbp:is_a_framework_for
|
generic drug market entry
|
|
gptkbp:is_a_key_component_of
|
drug approval timeline
|
|
gptkbp:is_a_law_that_has
|
broad implications for healthcare
influenced drug pricing strategies.
|
|
gptkbp:is_a_law_that_has_been
|
subject to reform discussions
|
|
gptkbp:is_a_law_that_impacts
|
drug development timelines
|
|
gptkbp:is_a_law_that_shapes
|
the competitive landscape of drugs
|
|
gptkbp:is_a_pivotal_law_in
|
the pharmaceutical sector
|
|
gptkbp:is_a_subject_of
|
gptkb:academic_research
legal challenges
policy debates
health economists
|
|
gptkbp:is_analyzed_in
|
economic impact studies
|
|
gptkbp:is_associated_with
|
drug innovation
|
|
gptkbp:is_cited_in
|
discussions about drug pricing
|
|
gptkbp:is_critical_for
|
U. S. pharmaceutical regulation
|
|
gptkbp:is_discussed_in
|
legal and economic studies
|
|
gptkbp:is_essential_for
|
consumer protection
|
|
gptkbp:is_evaluated_by
|
its effectiveness
|
|
gptkbp:is_involved_in
|
patent term extensions
|
|
gptkbp:is_linked_to
|
pharmaceutical marketing practices
|
|
gptkbp:is_often_discussed_in
|
drug patent expirations
|
|
gptkbp:is_often_referenced_in
|
gptkb:legal_case
|
|
gptkbp:is_part_of
|
U. S. healthcare system
|
|
gptkbp:is_related_to
|
biologics regulation
|
|
gptkbp:is_relevant_to
|
gptkb:Health_Insurance
drug patent law
|
|
gptkbp:is_significant_for
|
intellectual property rights
the context of drug affordability
|
|
gptkbp:is_studied_in
|
healthcare economics
|
|
gptkbp:known_as
|
gptkb:Drug_Price_Competition_and_Patent_Term_Restoration_Act
|
|
gptkbp:legal_framework
|
generic competition
|
|
gptkbp:legislation
|
generic drug approval process
|
|
gptkbp:notable_wins
|
generic drug manufacturers
|
|
gptkbp:provides
|
market exclusivity for brand-name drugs
|
|
gptkbp:purpose
|
to encourage the development of generic drugs
|
|
gptkbp:reduces
|
the time for generic drug approval
|
|
gptkbp:was_a_factor_in
|
pharmaceutical patent strategy
the pharmaceutical supply chain
|
|
gptkbp:bfsParent
|
gptkb:Orrin_Hatch
|
|
gptkbp:bfsLayer
|
5
|